Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Carisma Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Carisma Therapeutics Inc.

CARM

Carisma Therapeutics Inc.

About Carisma Therapeutics Inc.

Carisma Therapeutics develops engineered macrophage and monocyte therapies for cancer and liver fibrosis. Its platform leverages CAR technology and mRNA/LNP delivery to create off-the-shelf and in vivo treatments targeting solid tumors and fibrotic diseases. The company collaborates with Moderna on in vivo CAR-M programs and owns a broad intellectual property portfolio, focusing on immuno-oncology and immunologic diseases with potential for milestone and royalty revenues.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Carisma Therapeutics Inc.

1
1
Carisma Therapeutics Inc. Carisma Therapeutics Reports $45.3M in Collaboration Revenues and $44.7M Net Income for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Carisma Therapeutics Inc. Carisma Therapeutics Reports Financial Decline and Strategic Shift Amid Merger Plans

Via official filing (AI summary) | 11 months ago | 0 comments

3
1
Carisma Therapeutics Inc. Carisma Therapeutics Reports $9.3 Million Net Loss in Q1 2025, Focuses on Strategic Alternatives

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Carisma Therapeutics Inc. Carisma Therapeutics Reports $60.5M Net Loss for 2024, Collaboration Revenues Increase

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Carisma Therapeutics Inc. Carisma Therapeutics Reports Significant Financial Decline, Uncertainty Over Future Funding

Via official filing (AI summary) | over 1 year ago | 0 comments